Overview

ICON6 is a randomised three-arm, three stage, double-blind, placebo-controlled multi-centre Gynaecologic Cancer InterGroup (GCIG) phase III trial.  

ICON6 is designed to evaluate the safety and efficacy of platinum-based chemotherapy in combination with cediranib in women with platinum-sensitive relapsed ovarian cancer . Cediranib is an oral targeted small molecule inhibitor of a key signalling molecule Vascular Endothelial Growth Factor (VEGF) which is an oral inhibitor of tyrosine kinase (TK) activity and acts through blockade of the TK receptor. Cediranib (AZD2171) will be administered during platinum-based chemotherapy only (concurrent cediranib), or given during chemotherapy and continued as single agent maintenance therapy (concurrent and maintenance cediranib).